Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 711-713    DOI: 10.12892/ejgo5111.2019
Review Previous articles | Next articles
Hypoxia and its importance in the course of gynaecological cancers
A. Markowska1, *(), A. Huczyński3, Z. Kojs4, D. Twardawa5, J. Markowska2
1Department of Perinatology and women's Diseases, Poznan University of Medical Sciences, Poland
2Department of Oncology, Poznan University of Medical Sciences, Poland
3Faculty of Chemistry, Adam Mickiewicz University, Poznan, Poland
4Department of Gynecology Oncology, Center of Oncology M. Sklodowska-Curie Institute, Cracow Branch, Poland
5Swedish Orphan Biovitrum Ltd., warsaw, Poland
Download:  PDF(321KB)  ( 197 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Hypoxia-oxygen deficiency is a feature of most solid malignant tumours. This leads to the selection of an aggressive neoplasm phenotype by activating molecular factors including hypoxia inducible factor 1α (HIF-1α), vascular endothelial growth factor (VEGF) promoting angiogenesis, and also by the influence of the tumour microenvironment, no possibility of fixation of DNA damage after radio- and chemotherapy, and the change in cadherin activity. Another mechanism of hypoxia facilitates the survival, and activity of cancer stem cells (CSCs). The described therapies eliminating hypoxia include the use of cytotoxins, anaerobic bacteria, YC-1 factor, arsenic trioxide (As2O3), and eradication of CSCs by using retinoic and ursolic acid. The paper describes hypoxia as the cause of failure in the treatment of gynaecological cancers and therapies eliminating it.

Key words:  Hypoxia-oxygen deficiency      Angiogenesis      Gynaecological cancers     
Published:  10 October 2019     
*Corresponding Author(s):  A. MARKOWSKA     E-mail:  annamarkowska@vp.pl

Cite this article: 

A. Markowska, A. Huczyński, Z. Kojs, D. Twardawa, J. Markowska. Hypoxia and its importance in the course of gynaecological cancers. European Journal of Gynaecological Oncology, 2019, 40(5): 711-713.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo5111.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/711

[1] A. Markowska, W. Bednarek, R. Jach, A. Czekała, J. Markowska. Uterine fibroids: a new insight into an old problem[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 915-918.
[2] F. Barra, C. Bondi, C. Scala, V. G. Vellone, S. Ferrero. Pazopanib for the treatment of gynecological malignancies[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 702-708.
[3] H.Y. Xu, Y. Wang, H. Zhang, J. Xu. The long non-coding RNA UCA1, as a prognostic biomarker for high grade serous ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 883-889.
No Suggested Reading articles found!